Business
GT Biopharma Announces Interim GTB-3550 Trike™ Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference
57% of patients experienced significant reduction in AML/MDS cancer cell burden Up to 63.7% reduction in bone marrow blast levels observed in some patients
About this update from Gt Biopharma, Inc.
[{"type":"text","content":"57% of patients experienced significant reduction in AML/MDS cancer cell burden\n Up to 63.7% reduction in bone marrow blast levels observed in some patients\n\n\nBEVERLY HILLS, Calif., June 23, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE™) protein biologic technology platform, announced Jeffrey S. Miller, M.D., Deputy Director of the Masonic Cancer Center and Consulting Chief Scientific Officer, provided an update concerning GTB-3550 TriKE™ monotherapy clinical trial interim results at the 2021 Raymond James Health Innovation Conference. The presentation will be available on the \"News & Media\" page of the GT Biopharma website at www.gtbiopharma.com/news-media/presentation. \n\n \n \n \n \n \n \n\n \nHighlights to date from patients treated with GTB-3550 TriKE™ monotherapy in the dose escalation Phase 1 clinical trial for the treatment of high-risk MDS and refractory/relapsed AML:\n57% of patients experienced significant reduction in AML/MDS cancer cell burden when treated with doses of GTB-3550 ranging from 25mcg/kg/day to 150mcg/kg/day. Up to 63.7% reduction in bone marrow blast levels observed in some patients. GTB-3550 was well tolerated by all patients with no cytokine release syndrome observed. Restoration of patient's endogenous NK cell function, proliferation and immune surveillance observed in all patients – No progenitor-derived or autologous/allogenic cell therapy required.The on-going Phase 1 clinical trial of GTB-3550 TriKE™ monotherapy is focused on evaluating safety, and the determination of the recommended Phase 2 dose (RP2D), dose schedule and the maximum tolerated dose (MTD). Additional information is being collected concerning anti-tumor activity against CD33+ acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cancer cells, and restoration of the patient's exhausted/inhibited endogenous NK cell population. To date, 11 patients have completed treatment in the GTB-3550 Phase 1 clinical trial. Patient 5, Patient 7, Patient 9, Patient 11 experienced 33%, 61%, 63% and 50% reduction in CD33+ AML/MDS bone marrow blast levels, respectively. The Phase 1 safety part of the study is expected to conclude in late August 2021 with data publication current...